Schedule 13G ownership disclosure
Zevra Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 488445206
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Nantahala Capital Management, LLC
Shares: 2,340,333.00 · Class: 4.38%
- Wilmot B. Harkey
Shares: 2,340,333.00 · Class: 4.38%
- Daniel Mack
Shares: 2,340,333.00 · Class: 4.38%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-014205
- Form type
- SCHEDULE 13G/A
- Filer
- Nantahala Capital Management, LLC
- CIK
- CIK 1472322
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership